FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807788347> ?p ?o ?g. }

• W2807788347 abstract "Objectives Corticosteroids (CS) are accepted as the standard first-line treatment for giant cell arteritis (GCA). However, controlled trials of tocilizumab and abatacept demonstrated relapse rates of up to 70%–80% in patients on CS-only protocols in 12–24 months. Though level of evidence is low and not suggested by guidelines (except for methotrexate), conventional immunosuppressives (ISs) are also commonly used. We aimed to assess the relapse rates in patients with GCA in routine practice, retrospectively. Methods We assembled a retrospective cohort of patients with GCA from Turkey. All data was abstracted from records. Relapse was defined as any new manifestation or increased acute-phase response leading to the change of the CS dose or use of a new therapeutic agent by the treating physician. Results The study included 156 (F/M: 95/61) patients with GCA (table 1). The mean age at disease onset was 67.8±9.1 years. Polimyalgia Rheumatica was also present in 48 (30,8%) patients. Diagnosis was proven histopathologically in 99 patients.All patients received 1 mg/kg/day CS for remission induction, additional CS pulses were given to 36 (23.1%) patients. Conventional ISs including methotrexate and azathioprine were used in 89 (56.1%) and 26 (16.6%) patients respectively, while 10 (6.4%) patients received biologic treatments (8 tocilizumab,2 etanercept). Fourty-four (28.2%) patients used only CS during follow-up. Follow-up of at least 6 months was available for 132 patients, and median follow-up duration was 35 (6–268) months. Relapses occurred in 27 (20.5%) patients during follow-up. Mortality rate was 7.5% (n=10) during follow-up. VDI score was 2.4±1.7. Main causes of damage were related to CS treatments such as cataract, osteoporosis and diabetes mellitus. Conclusions In this first multi-centre series of GCA from Turkey, we observed that only one fifth of patients had relapses during a mean follow-up of 35 months. This lower relapse frequency suggests a different clinical spectrum in routine practice compared to patients included in controlled trials. Our results also suggest that there is a clear need for a steroid sparing agent in patients with GCA, that is a older aged population prone to CS side effects. Disclosure of Interest None declared" @default.
• W2807788347 created "2018-06-21" @default.
• W2807788347 creator A5003684500 @default.
• W2807788347 creator A5004616065 @default.
• W2807788347 creator A5007037761 @default.
• W2807788347 creator A5013802254 @default.
• W2807788347 creator A5014114164 @default.
• W2807788347 creator A5015504748 @default.
• W2807788347 creator A5015553608 @default.
• W2807788347 creator A5019220311 @default.
• W2807788347 creator A5019796937 @default.
• W2807788347 creator A5020805182 @default.
• W2807788347 creator A5023364913 @default.
• W2807788347 creator A5024427640 @default.
• W2807788347 creator A5027358068 @default.
• W2807788347 creator A5027714561 @default.
• W2807788347 creator A5029797000 @default.
• W2807788347 creator A5032970295 @default.
• W2807788347 creator A5041518880 @default.
• W2807788347 creator A5047368082 @default.
• W2807788347 creator A5053850680 @default.
• W2807788347 creator A5067709132 @default.
• W2807788347 creator A5068477645 @default.
• W2807788347 creator A5077432852 @default.
• W2807788347 creator A5087693961 @default.
• W2807788347 creator A5087996145 @default.
• W2807788347 creator A5088234361 @default.
• W2807788347 creator A5051795470 @default.
• W2807788347 date "2018-06-01" @default.
• W2807788347 modified "2023-10-18" @default.
• W2807788347 title "SAT0526 Is relapse rate of giant cell arteritis in real-life experience lower than in the controlled trials? results of a retrospective, multi-centre cohort study" @default.
• W2807788347 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3983" @default.
• W2807788347 hasPublicationYear "2018" @default.
• W2807788347 type Work @default.
• W2807788347 sameAs 2807788347 @default.
• W2807788347 citedByCount "0" @default.
• W2807788347 crossrefType "proceedings-article" @default.
• W2807788347 hasAuthorship W2807788347A5003684500 @default.
• W2807788347 hasAuthorship W2807788347A5004616065 @default.
• W2807788347 hasAuthorship W2807788347A5007037761 @default.
• W2807788347 hasAuthorship W2807788347A5013802254 @default.
• W2807788347 hasAuthorship W2807788347A5014114164 @default.
• W2807788347 hasAuthorship W2807788347A5015504748 @default.
• W2807788347 hasAuthorship W2807788347A5015553608 @default.
• W2807788347 hasAuthorship W2807788347A5019220311 @default.
• W2807788347 hasAuthorship W2807788347A5019796937 @default.
• W2807788347 hasAuthorship W2807788347A5020805182 @default.
• W2807788347 hasAuthorship W2807788347A5023364913 @default.
• W2807788347 hasAuthorship W2807788347A5024427640 @default.
• W2807788347 hasAuthorship W2807788347A5027358068 @default.
• W2807788347 hasAuthorship W2807788347A5027714561 @default.
• W2807788347 hasAuthorship W2807788347A5029797000 @default.
• W2807788347 hasAuthorship W2807788347A5032970295 @default.
• W2807788347 hasAuthorship W2807788347A5041518880 @default.
• W2807788347 hasAuthorship W2807788347A5047368082 @default.
• W2807788347 hasAuthorship W2807788347A5051795470 @default.
• W2807788347 hasAuthorship W2807788347A5053850680 @default.
• W2807788347 hasAuthorship W2807788347A5067709132 @default.
• W2807788347 hasAuthorship W2807788347A5068477645 @default.
• W2807788347 hasAuthorship W2807788347A5077432852 @default.
• W2807788347 hasAuthorship W2807788347A5087693961 @default.
• W2807788347 hasAuthorship W2807788347A5087996145 @default.
• W2807788347 hasAuthorship W2807788347A5088234361 @default.
• W2807788347 hasBestOaLocation W28077883471 @default.
• W2807788347 hasConcept C126322002 @default.
• W2807788347 hasConcept C141071460 @default.
• W2807788347 hasConcept C167135981 @default.
• W2807788347 hasConcept C2776015282 @default.
• W2807788347 hasConcept C2776712624 @default.
• W2807788347 hasConcept C2776715498 @default.
• W2807788347 hasConcept C2776760755 @default.
• W2807788347 hasConcept C2777178219 @default.
• W2807788347 hasConcept C2777226972 @default.
• W2807788347 hasConcept C2777575956 @default.
• W2807788347 hasConcept C2779134260 @default.
• W2807788347 hasConcept C2779338263 @default.
• W2807788347 hasConcept C2779605438 @default.
• W2807788347 hasConcept C2780079024 @default.
• W2807788347 hasConcept C2780653079 @default.
• W2807788347 hasConcept C2781059491 @default.
• W2807788347 hasConcept C71924100 @default.
• W2807788347 hasConcept C72563966 @default.
• W2807788347 hasConceptScore W2807788347C126322002 @default.
• W2807788347 hasConceptScore W2807788347C141071460 @default.
• W2807788347 hasConceptScore W2807788347C167135981 @default.
• W2807788347 hasConceptScore W2807788347C2776015282 @default.
• W2807788347 hasConceptScore W2807788347C2776712624 @default.
• W2807788347 hasConceptScore W2807788347C2776715498 @default.
• W2807788347 hasConceptScore W2807788347C2776760755 @default.
• W2807788347 hasConceptScore W2807788347C2777178219 @default.
• W2807788347 hasConceptScore W2807788347C2777226972 @default.
• W2807788347 hasConceptScore W2807788347C2777575956 @default.
• W2807788347 hasConceptScore W2807788347C2779134260 @default.
• W2807788347 hasConceptScore W2807788347C2779338263 @default.
• W2807788347 hasConceptScore W2807788347C2779605438 @default.
• W2807788347 hasConceptScore W2807788347C2780079024 @default.
• W2807788347 hasConceptScore W2807788347C2780653079 @default.
• W2807788347 hasConceptScore W2807788347C2781059491 @default.
• W2807788347 hasConceptScore W2807788347C71924100 @default.
• W2807788347 hasConceptScore W2807788347C72563966 @default.

• next